滚动资讯
FierceBiotechFDA advisory committee set to weigh taking action on certain unapproved peptidesRoche MediaCould Roche’s Top-Selling Drug Be Harming Women with Primary Progressive Multiple Sclerosis? - Bioengineer.orgAgilentAgilent Technologies Inc stock (US00846U1016): Why its life sciences leadership matters more now for - AD HOC NEWS10x Genomics Blog10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026 - Moomoo10x Genomics BlogAfter the bell: 10x Genomics posts quarterly results May 7 - Stock Titan10x Genomics Blog10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026 - Yahoo FinanceEndpoints NewsScribing startup Abridge adds NEJM, JAMA as it moves into medical AI searchEndpoints NewsFDA weighs support for compounding popular peptidesEndpoints NewsBiotech stocks are on a tear againAgilentAgilent (A) Showcases Innovations at AACR 2026 Annual Meeting - GuruFocusBioPharma DiveBeeline, a Bain-backed biotech, debuts with immune drugs from Bristol MyersFierceBiotechLabcorp launches rapid fentanyl test with 48-hour detection window
FierceBiotech 2026年4月16日

FDA advisory committee set to weigh taking action on certain unapproved peptides

FDA advisory committee set to weigh taking action on certain unapproved peptides

原文
暂时没有全文，请查看原始来源。

目录

1122 全部